‘I don’t see a risk in producing data’ — Jallal’s philosophy at the heart of growing Immunocore

While some biotechs are circumspect about gathering data during clinical trials that might not support the product in question, Immunocore CEO Bahija Jallal sees it as part of the obligation to patients and the field to learn as much as possible, as efficiently as possible. And that strategy has informed how the company will take its TCR technology into earlier lines of treatment and new indications.

Jallal joined U.K.-based Immunocore Holdings plc (NASDAQ:IMCR) in 2019, having previously been president of Medimmune, the former Astrazeneca plc (LSE:AZN; NASDAQ:AZN) unit...